Abstract

Dermatoses are the group of diseases which involve all layers of the skin from the epidermis through the dermis and subcutaneous tissue, till appendages. The global burden of skin disease in populations is not currently monitored, therefore there is no data on the prevalence of skin diseases in the general population. However, from the epidemiological point of view, it is possible to point out the most common dermatoses and among them distinguish these diseases, which belong to chronic conditions with immunological origin e.g. atopic dermatitis, psoriasis, pemphigus, vitiligo and alopecia areata. Due to conducted studies and better diagnostics, unknown pathomechanisms of dermatoses are discovered and consequently new treatment methods are implemented. The therapeutic progress in the symptomatic treatment of autoimmune skin diseases is related to the introduction on the market of biological medical products called biopharmaceuticals. In this manuscript, the characterization of biopharmaceuticals is presented in terms of their applicability in the treatment of psoriasis. Psoriasis is the chronic dermatological disease with inflammatory response and non-infective character, which shows significant variations in the prevalence of European population. Typical symptoms of psoriasis are red, raised skin areas, covered with silvery scales, mainly appears within the upper and lower extremities face and head. Further in the manuscript, psoriasis is discussed as a public health problem, the pathogenesis of this disease is described and the characterization of the biopharmaceuticals used in psoriasis is presented. In the last part, the results of a systematic literature review (meta-analysis) on the etanercept, the biopharmaceutical used in psoriasis, is discussed.

Full text